DAX ®11.423,28+0,19%TecDAX ®2.601,85-0,53%Dow Jones25.850,63-0,40%NASDAQ 1007.035,16-0,38%
finanztreff.de

PRESS RELEASE: iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement

| Quelle: Dow Jones Newswire Web | Lesedauer etwa 6 min. | Text vorlesen Stop Pause Fortsetzen
PRESS RELEASE: iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement

Dow Jones received a payment from EQS/DGAP to publish this press release.




DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous
iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to
its C$750,000 Non-Brokered Private Placement

2019-02-12 / 01:20
The issuer is solely responsible for the content of this announcement.

Vancouver, British Columbia(Newsfile Corp. - February 11, 2019) - iCo
Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is
pleased to announce that it has issued a total of 4,000,000 units (the
"Units") to a Canadian institutional investor pursuant to its previously
announced non-brokered private placement (the "Private Placement"). The
Units were sold at a price of $0.05 per Unit, for total gross proceeds to
the Company of C$200,000.

Each Unit issued pursuant to the Private Placement consists of one common
share in the capital of the Company (a "Common Share") and one common share
purchase warrant (a "Warrant") exercisable at $0.075 for 36 months from the
date of the closing of the Private Placement. The Warrants are subject to an
acceleration clause (the "Acceleration Clause") that allows the Company to
accelerate the expiry date of the Warrants in the event that, at any time
after four months from the closing date, the volume weighted average trading
price of the Common Shares on the TSX Venture Exchange equals or exceeds
$0.14 for ten consecutive trading days, the Warrants will expire on the date
that is at least 30 days following the issuance of a press release
announcing such acceleration from the Company.

The Company has agreed (i) to pay a cash finder's fee of 8% of the gross
proceeds to the Company raised from subscriptions in the Private Placement
from persons introduced to the Company by certain finders and (ii) to issue
compensation warrants (the "Finders' Warrants") equal to 8% of the Units
subscribed for by persons introduced to the Company by certain Finders. Each
Finders' Warrant will entitle the finder to purchase one additional Common
Share for a period of 24 months from the closing of the Private Placement at
an exercise price of $0.05 per Finders' Warrant.

The Private Placement is expected to occur in several closings, concluding
on or about February 18, 2019, and is subject to the receipt of all
necessary regulatory approvals, including the approval of the TSX Venture
Exchange. All securities issued pursuant to the Private Placement will be
subject to a four month hold period in accordance with applicable Canadian
securities laws. There is no material fact or material change regarding iCo
that has not been generally disclosed.

The Company intends to use the net proceeds from the Private Placement for
working capital and general corporate purposes.

*This press release does not constitute an offer to sell or a solicitation
of an offer to sell any of the securities in the United States. The
securities have not been and will not be registered under the United States
Securities Act of 1933, as amended (the "1933 Act") or any state securities
laws and may not be offered or sold within the United States or to U.S.
Persons unless registered under the 1933 Act and applicable state securities
laws or an exemption from such registration is available.*

*About iCo Therapeutics *

iCo Therapeutics identifies existing development stage assets for use in
underserved ocular and infectious diseases. Such assets may exhibit utility
in non-ophthalmic conditions outside the Company's core focus areas and if
so the Company will seek to capture further value via partnerships, such as
its partnership with Immune Pharmaceuticals, which is in several Phase 2
studies involving iCo-008. iCo shares trade on the TSX Venture Exchange
under the symbol "ICO" and on the OTCQB under the symbol "ICOTF".

For more information, visit the Company website at: www.icotherapeutics.com
[1].

_No regulatory authority has approved or disapproved the content of this
press release. Neither the TSX Venture Exchange nor its Regulatory Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this press
release._

*Forward-Looking Statements*

Certain statements included in this press release may be considered
"forward-looking information" within the meaning of applicable securities
laws. Forward-looking information can be identified by words such as:
"anticipate", "intend", "plan", "goal", "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will" and similar references to future periods. Such statements involve
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. Forward-looking
statements in this press release include statements relating to the timing
and completion of the Private Placement and the use of proceeds therefrom.
All forward-looking statements are based on iCo's current beliefs as well as
assumptions made by and information currently available to iCo and relate
to, among other things, anticipated financial performance, business
prospects, strategies, regulatory developments, market acceptance and future
commitments. Readers are cautioned not to place undue reliance on these
forward-looking statements, which are based only on information currently
available to iCo and speak only as of the date of this press release. Due to
risks and uncertainties, including the risks and uncertainties identified by
iCo in its public securities filings and on its website, actual events may
differ materially from current expectations. iCo disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as required by
law.

*Contact:*

Andrew Rae
Chief Executive Officer
iCo Therapeutics Inc.
rae@icotherapeutics.com
1-778-772-7775 (c)

*NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES*

To view the source version of this press release, please visit
https://www.newsfilecorp.com/release/42768 [2]

Click on, or paste the following link into your web browser, to view the
associated documents http://www.newsfilecorp.com/release/42768

2019-02-12 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: iCo Therapeutics Inc.

Canada
ISIN: CA45107J1057

End of News DGAP News Service

774789 2019-02-12


1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=11273aeabc279950950deb975b91f278&application_id=774789&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=184c4e23aa005559c2e7513675767732&application_id=774789&site_id=vwd&application_name=news


(END) Dow Jones Newswires

February 11, 2019 19:20 ET ( 00:20 GMT)
Werbung

Das könnte Sie auch interessieren

Werbung
Werbung

News-Suche

Suchbegriff:
Werbung

Aktuelle Videos

zur Mediathek
Werbung

Werbung
Börse Stuttgart Anlegerclubschliessen
Börse Stuttgart

Wir machen Sie fit für die Börse!

Aktuelle Nachrichten, umfangreiche
Hintergrundinformationen und essentielles
Finanzwissen rund um das Thema Börse.

Jetzt kostenfrei zum Anlegerclub anmelden.
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
In Templin, einer Stadt in der Uckermark, soll ein sehr eigenwilliges Projekt in einer Schule eingeführt werden. -Lieber schlau statt blau- soll der Suchtvorbeugung dienen. Schüler sollen in der Schule kontrolliert Alkohol trinken und die Folgen aktiv beobachten. Finden Sie die Idee gut?
Jetzt abstimmen!
Alle Umfragen ansehen